Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bioxcel Therapeutics ( (BTAI) ) just unveiled an announcement.
On August 6, 2025, BioXcel Therapeutics announced the publication of a study in Frontiers in Pharmacology, highlighting the effects of dexmedetomidine on stress-mediated behaviors. The study demonstrated that dexmedetomidine, the active ingredient in BXCL-501, showed significant potential in treating stress-related disorders beyond acute agitation, with favorable attributes for daily use and no adverse effects on motor function or cognition.
The most recent analyst rating on (BTAI) stock is a Buy with a $112.00 price target. To see the full list of analyst forecasts on Bioxcel Therapeutics stock, see the BTAI Stock Forecast page.
Spark’s Take on BTAI Stock
According to Spark, TipRanks’ AI Analyst, BTAI is a Underperform.
Bioxcel Therapeutics’ stock is rated at the lowest end of the scale due to substantial financial instability, including ongoing losses, high debt, and negative cash flows. Short-term technical indicators and valuation metrics further highlight the current challenges. The company needs to address these financial and operational issues to improve its stock performance.
To see Spark’s full report on BTAI stock, click here.
More about Bioxcel Therapeutics
BioXcel Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development of innovative medicines for the treatment of neuropsychiatric and neurological disorders. Their primary product, BXCL-501, is a sublingual film formulation of dexmedetomidine, targeting acute agitation and potentially other chronic conditions.
Average Trading Volume: 2,108,184
Technical Sentiment Signal: Sell
Current Market Cap: $8.3M
Learn more about BTAI stock on TipRanks’ Stock Analysis page.